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immunoassay methods for the detection of Chlamydia 
trachomatis antigen in endocervical specimens 
Old fur  Steingrimsson ', Catherine Pawlak2, Barbara Van Der Pol 3,  Bufy l? Turner4, 
Jbn Hjaltalin Olafison *, Lauren Dolphin2, James E. Williams3, Cynthia E. Peyton4, 
Robert E.  Kleppe?, Robert €3. Jones', Garland D. Anderson4, Neda Rashti', 
Alice S. Weissfeld and Allan Pronovost2 
'University of Iceland, Reykjavik, Iceland; and *Quidel Corporation, San Diego, California, 
Galveston, Texas, USA 
Indiana University Medical Center, Indianapolis, Indiana, and  4Univer~i ty  of Texas Medical Branch, 
Objective: To evaluate two rapid immunoassay methods, QuickVue-Chlamydia (Quidel Corp., San Diego California) 
and Kodak SureCell (Kodak Corp., Rochester, NY) for the detection of Chlamydia trachomatis antigen in endocervical 
swabs from high- and low-risk females. 
Methods: Seven hundred and twenty-four females attending three clinics were enrolled in the study. The results were 
compared to  McCoy's or BGMK cell culture and discrepancies resolved with polymerase chain reaction and direct 
fluorescent antibody tests performed on left-over culture specimens. 
Results: The sensitivity, specificity, predictive value of a positive and predictive value of a negative of the QuickVue 
Chlamydia assay were 92.0%, 99.1%, 92.0% and 99.1%, respectively. The sensitivity, specificity, predictive value of a 
positive and predictive value of a negative of the SureCell assay were 90.0%, 99.8%, 98.6% and 98.8%. respectively. 
Conclusions: The performances of the two immunoassay methods were similar, and slight differences in sensitivity 
and specificity were not statistically significant. Both immunoassay methods performed well in high- and low-risk patient 
groups, both for symptomatic and for asymptomatic patients. 
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Genital infections caused by Chlamydia trachomatic. have 
been a significant healthcare problem in the Western 
world in recent years [l]. Cell culture has been the 
traditional method for diagnosing these infections but 
it is expensive and time-consuming. Rapid diagnosis of 
chlamydia1 infections is obviously of major importance 
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for efficient treatment of individual patients and for 
effective contact tracing. Since a significant number of 
patients are asymptomatic, screening of asymptomatic 
populations may be of major importance. In recent 
years a number of rapid methods have been introduced 
for direct detection of chlamybd antigens in patient 
specimens [2-51. These rapid tests have come into 
widespread use, although they have lacked sensitivity 
compared to culture. Initially, most of these new rapid 
tests were intended for use in laboratories, but more 
recently tests have been introduced for use in doctors' 
offices or at the bedside [6-lo]. Taking the test to the 
patient instead of having to send a specimen to a 
laboratory can obviously save significant time and save 
patients some anxiety. The performance of two rapid 
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test methods was compared with culture in low- and 
high-risk females. The tests were the Kodak Surecell, 
which has been on the market for some time, and 
the Quidel QuickVue test, which has been recently 
introduced. 
MATERIALS AND METHODS 
Study centers 
This collaborative study was carried out in three centers 
under the coordination of the Quidel Corporation. 
The centers were the University of Iceland, School of 
Mehcine, Reykjavik, Iceland (UI), Indiana University 
Medical Center, Indianapolis, Indiana (IU) and the 
University of Texas Medical Branch, Galveston, Texas 
(UT). All centers used similar culture procedures for 
Chlamydia trachomatis and the immunoassays were per- 
formed according to manufacturers' recommendations. 
Patient populations 
The patients studied at UI and IU were at high risk 
for sexually transmitted diseases (STD). These were 
individuals attending STD clinics in Reykjavik and 
Indianapolis either because of symptoms or because 
they were contacts of persons thought to be infected 
with STD. The population studied at UT was at low 
risk: individuals attending either a family planning clinic 
or an obstetrics and gynecology clinic in Galveston, 
Texas. 
Specimens 
Three endocervical swabs were collected from each 
individual at IU and UT. The specimen for culture 
was always collected first and the specimens for the 
two immunoassays collected second and third in an 
alternating sequence. At UI, the first three were 
collected in an alternating sequence for culture and the 
two rapid tests. The specimens were transported daily 
at 4 4 ° C  to the respective laboratories where the two 
immunoassays were performed, and the culture was 
inoculated within 72 h of collection or the culture 
specimen was frozen at -7OOC until processing. The 
transport media used were 1.3 mL of Chlamydia Trans- 
port Medium [ll] at UI, 2.0 mL of SPG-VGN 
Transport Medium at IU (Baxter Diagnostics, McGaw 
Park, IL) and 3.0mL of M-4 at UT (Baxter 
Diagnostics, McGaw Park, IL). 
Cell culture 
There were some variations in the culture procedures 
used at the different laboratories. At UT the swab 
in 3.0mL. of transport medium was vortexed, and 
0.25mL of the medium was added to BGMK cell 
(American Type Culture Collection, Rockville Mary- 
land) monolayers in shell vials. After centrifugation 
(3000-3200 rev/min at 30-35"C, 60 min), 1.00 mL of 
Ortho Chlamydia Isolation Medium (Ortho Diag- 
nostic Systems, Raritan, NJ) was added and cultures 
were incubated for 48-72 h at 37°C. Five methanol- 
fixed coverslips were mounted on glass slides and 
stained with FITC fluorescent monoclonal antibody 
(Siva Co., Palo Alto, CA). Each coverslip was scanned 
under the fluorescent microscope at x10, x20 or x40 
magnification for chlamydial inclusions. At IU, the 
swab in 2.0 mL of transport medium was brought to 
room temperature, and after vortexing and sonication, 
0.10 mL of the medium was added to a McCoy cell 
(American Type Culture Collection, Rockville, Mary- 
land) monolayer on a microtiter plate and supple- 
mented with 0.2 mL of MEM-VGA Medmm (Baxter 
Diagnostics, McGaw Park, IL). Plates were sealed and 
centrifuged at 2500 rev/min for 1 h at 30°C. Following 
incubation for 48-72 h at 37"C, methanol-fixed 
monolayers were layered with chlamydia mouse 
antiserum (L127/1A7), and incubated for 30min at 
room temperature; this was followed by phosphate- 
buffered saline (PBS) washes. PBS was then removed 
and FITC-antimouse conjugate was added and washed 
in the same manner. Morphology was confirmed using 
a fluorescent microscope at x25-40 magnification. 
At UI, the swab in 1.3 mL of Chlamydia Transport 
Medium was brought to room temperature and, after 
vortexing, 0.50mL of the medium was added to 
McCoy cell monolayers in shell vials. After centri- 
fugation (5500 rev/min at room temperature, 1 h), 
transport medium was removed and 1.0 mL of main- 
tenance medium was added. Cultures were incubated 
for 48-72 h at 35OC. Duplicate methanol-fured cover- 
slips were mounted on glass slides, cells up, and one 
was stained immediately with Micro Trak Culture 
Confirmation Reagent (Siva Co., Palo Alto, CA). 
Coverslips were scanned under the fluorescent micro- 
scope at x10 magnification and confirmed at x40 
magnification for chlamydial inclusions. If the exami- 
nation was inconclusive, the second was subcultured; 
otherwise it was stained with iodine. 
QuickVue and SureCell testing protocol 
QuickVue Chlamydia Test 
The endocervical swab is placed in an alkaline extrac- 
tion solution. Two minutes later, after adhtion of 
the neutralization reagent, three drops of the sample 
are added to the test cassette sample well. The test 
device is a lateral-flow, one-step sandwich immuno- 
assay. Capture antibody is bound irreversibly to the test 
strip in the form of a narrow test line. Detection 
antibody conjugated to red-dyed label is immobilized 
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in dry form on the test strip. When the sample is added 
to the device, it dissolves the label and carries it along 
the test strip by means of capillary action. If present in 
the sample, chlamydia antigen binds to the red label 
and subsequently to the capture antibody. The result of 
this sandwich, a distinct red test line, signals a positive 
result. 
Kodak Surecell Chlamydia Test Kit 
The sample is extracted via a three-step procedure 
consisting of 1-, 1- and 2-min incubation steps 
following sequential addition of the extraction reagents 
to the tube containing the swab. The test is an eight- 
step enzyme immunoassay in a flow-through format. 
There is no capture antibody. Chlamydia antigen, if 
present in the sample, binds directly to the membrane, 
and after multiple washing steps is detected by horse- 
radish peroxidase-labeled monoclonal antibody. An 
enzyme substrate added in the last step creates red color 
in the test well which is indicative of the presence of 
chlamydia antigen. 
Both assays take about 10 min to perform, but the 
QuickVue Chlamyha test is easier to perform because 
it requires just the addition of the extracted sample to 
the test device without subsequent application of the 
reagents and washing steps. 
Swabs for the rapid methods were transported 
daily to the laboratory, dry in plastic tubes. They were 
extracted and the results interpreted on the same day 
according to the corresponding package insert. Results 
were visually scored as positive, negative or uninter- 
pretable. 
Resolution of discrepant results 
Clinical specimens extracted for QuickVue and Sure- 
Cell are not suitable for confirmatory testing because 
of the destructive character of the extraction procedure. 
The remaining culture transport media samples were 
frozen at -70°C and tested in two ways. One-third of 
the retained medium was centrifuged and the resulting 
sediment was tested with the Amplicor P C R  (Roche 
Molecular Systems) according to the urine protocol in 
the package insert at the Indiana University School of 
Medicine, Infectious Disease Laboratory. Another third 
of the remaining culture medium was examined by 
Syva MicroTrak Chlamydia trachomatis Direct Specimen 
Test (fluorescent antibody). ‘False-positive’ QuickVue 
and SureCell tests were converted to true positives if 
either of the confirmatory tests or the rapid test on the 
sister specimen were positive. 
Statistical tests 
Sensitivity, specificity, and predictive values were deter- 
mined by the method of Galen et al [12]. 
The patients were 358 females a t  low risk and 366 at 
high risk, a total of 724. The overall prevalence of 
positive cultures was 10.1%, but the prevalence of 
infection was 11% if corrected culture results, i.e. 
positive culture results plus negative culture results 
when the subjects of the latter were positive in a 
confirmatory test or in the alternate rapid test, were 
used as the standard. The sensitivity of culture was thus 
91%. Table 1 presents the combined results of the 
two immunoassays for the detection of C .  trachomatis 
compared with corrected culture results. The figures 
in Table 1 include both asymptomatic (81% in the 
low-risk group and 59% in the high-risk group) and 
symptomatic patients. There was no statistically signi- 
ficant difference in the performance of the two 
tests between symptomatic patents and asymptomatic 
patients. The overall sensitivities of QuickVue and 
SureCell were 92.3% and 90.0%, respectively, and the 
specificities were 99.1% and 99.8%, respectively. The 
predictive values of a positive (PVP) QuickVue or 
SureCell result were 92.3% and 98.6%, respectively, and 
the predictive values of a negative (PVN) QuickVue or 
SureCell result were 99.1% and 98.8%, respectively. 
The number of inclusions per d in the 73 
specimens with positive culture and the performances 
Table 1 Comparison of two enzyme immunoassay tests for 
C. trachomatis with corrected culture results for 724 female 
patients 
Number of Nuinher o f  
positive tests negative tests 
Corrected 
culture results QuickVue SureCell Quickvile SureCell 
Po$ltlve 72 72 6 8 
Negative 6 1 639 642 
Total 78 73 64.5 650 
Table 2 Performance of the two tests in four categories of 
specimens based on the number of inclusions per mL of 
culture inoculum 
Culture Quic kVue SureCell 
Sensitivity Sensitivity 
IC/mL No. Positive (%) Positive (5%) 
>lo“  5 5 100 5 100 
10’-10‘ 29 28 97 28 97 
lO”10’ 23 21 91 20 87 
<10* 16 13 81 12 75 
Total 73 67 92 65 8‘) 
IC, inclusions. 
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of the two tests in each of four categories are shown 
in Table 2. The performances of the two tests in 
asymptomatic and symptomatic patients in both high- 
and low-risk patients are shown in Table 3. 
Table 4 presents a compilation of the test results 
from the three sites. The patients tested at the Texas 
University site were low-risk patients with a disease 
prevalence of 4.7%, but the patients at the Universities 
of Indiana and Iceland were at high risk, with disease 
prevalences of 10.3% and 17.9%, respectively. The 
greatest difference of 15.4% in the sensitivity ofthe two 
tests was observed at the Indiana University site: 84.6% 
(QuickVue) versus 69.2% (Surecell), with 95% con- 
fidence for the difference of 5.2-25.6%. The overall 
difference in sensitivity of the two tests was not 
statistically significant (92-90%, or 2%, with a 95% 
confidence interval of -2.3% to 6.3%). 
DISCUSSION 
Many new diagnostic tests have emerged for the diag- 
nosis of C. trachomatis infections in recent years. None 
of them are perfect nor are any of them ideal for use in 
all situations. Cell culture, the traditional method, is 
time-consuming, technically diacult and expensive. 
Although culture is highly specific, it sometimes lacks 
sensitivity [13], as the specimens used for culture need 
to be transported to the laboratory under controlled 
Table 3 Performance of the two immunoassays in 724 
high- and low-risk patients broken down into groups of 
symptomatic and asymptomatic patients 
QuickVue SureCell 
Sensitivity Specificity Sensitivity Specificity 
No. (%) (“A) (%) (”/.I 
High risk 
Asymptomatic 216 97 100 90.9 100 
Symptomatic 150 88 98.4 88 100 
Asymptomatic 290 88 99 88 100 
Low risk 
Symptomatic 68 100 97 100 98 
conditions. At present, the widespread use of antigen- 
detection methodology decreases result turnaround 
time and reduces hands-on technical time when 
diagnosing these infections. Many of the antigen- 
detection tests are intended for use in clinical labora- 
tories but some, such as the two evaluated here, 
are intended for use in physicians’ offices. Antigen- 
detection methods have traditionally demonstrated less 
sensitivity than cell culture for the detection of these 
infections [5]. The sensitivity is heavily dependent on 
the patient population studied, with the lack of 
sensitivity being most pronounced in asymptomatic 
males [2,5]. Diagnostic tests perform best, in terms of 
sensitivity and the predictive value of a positive, in 
young, high-risk females. The amount of antigen in an 
infected cervical canal is related to age, decreasing with 
increasing age of the patient. Our patients were mostly 
young, high-risk females with high inclusion counts on 
culture (Table 2). 
The two tests, the QuickVue and Surecell, per- 
formed extremely well compared to culture in this 
study, and the latter better than previously reported 
[7-lo]. As seen in Table 2, there are greater differences 
in the sensitivity of the tests at the different clinic sites 
than between the two tests at each site. This undoubt- 
edly reflects a difference in the patient populations 
and local conditions that relate to the quality of the 
specimen and the delivery conditions of the specimen. 
The new molecular methods, polymerase chain 
reaction (PCR) and the ligase chain reaction (LCR), 
have typically exhibited higher sensitivity than that 
of the traditional method, cell culture [13-171. The 
sensitivity of cell culture has been estimated to be 
70-90% at best. 
In this study the rapid tests were performed in 
central laboratories. Great emphasis was placed on 
specimen handling and short transit times to ensure 
minimal loss of specimen quality. The two rapid tests 
are designed for use at the patients’ bedside, which 
would constitute a considerable advantage in locations 
where access to central laboratories is limited. The 
relatively good performance of both tests in asymp- 
tomatic low-risk patients is noteworthy. 
Table 4 Individud-laboratory comparison of the QuickVue and Surecell tests with corrected culture in high- and low-risk 
female patients 
Scnsitivity (“Yo) Specificity (%) 
Risk group No. of patients Prevalence (96) QuickVue SureCeU QuickVue Surecell 
Texas University Low risk 358 4.7 90.0 90.9 98.8 99.7 
Indiana University High risk 126 10.3 84.6 69.2 100 100 
University of Iceland High risk 240 17.9 95.6 95.6 99.0 100 
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In conclusion it can be said that both of the 
antigen-detection tests studied are likely to perform 
quite well when used on patient groups like the ones 
included in this study, especially when full advantage 
can be taken of the rapidity with which the results 
can be obtained, such as in physicians’ offices. The 
QuickVue test has the added advantage over the Sure- 
Cell test of being somewhat simpler to perform. 
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